Fox Chase Cancer Center study shows that inhibitors of (FAP) attenuate tumor growth in mice

PHILADELPHIA, PA (BUSINESS WIRE) A study conducted by researchers at Fox Chase Cancer Center supports a possible novel approach for attacking cancer.

The research involves two inhibitors of fibroblast activation protein (FAP), which has been implicated in human tumor growth. Talabostat (PT-100) and PT-630-- developed by Point Therapeutics (Boston, Mass.) suppressed tumor growth in mouse models, according to new data presented today at the American Association for Cancer Research 97th Annual Meeting in Washington, D.C., by Jonathan Cheng, M.D., Fox Chase Cancer Center.

FAP is a member of the DPP family, which are enzymes that appear to regulate several different physiological processes including tumor growth and immune responses.

Cheng's study demonstrated that both PT-100 and PT-630 inhibited FAP enzymatic activity and attenuated tumor growth in mice. PT-100 has been reported to upregulate the production of cytokines and chemokines leading to stimulation of the innate and adaptive immune system. In contrast, PT-630 inhibits FAP activity but is not known to induce cytokine and chemokine upregulation. Fox Chase scientists used mice that lack an adaptive immune system due the absence of T and B lymphocytes to control for talabostat's immunostimulatory activity and isolate the role of FAP in tumor growth. "The anti-tumor activity of both talabostat and PT-630 is intriguing because it suggests a mechanism of action involving tumor-targeted FAP inhibition that may be distinct from immune stimulation in tumor types where FAP is expressed clinically," said Cheng. "This may be a potentially novel way to treat cancer."

About fibroblast activation protein (FAP)

Fibroblast activation protein is a member of the dipeptidyl peptidase (DPP) family of serine proteases that is not present in most healthy tissues but is expressed on the tumor stroma of epithelial cancers, melanoma, and by certain sarcomas. It

Contact: Rachel Martin
Edelman Public Relations

Page: 1 2

Related biology news :

1. DoD awards $10.7 million Center of Excellence Grant to Fox Chases V. Craig Jordan
2. Fox Chase study sheds light on cancer susceptibility and disease involving bone-marrow failure
3. Symposium honors achievements of Fox Chase Cancer Center Nobel Laureate Baruch Blumberg
4. Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage
5. Fox Chase Cancer Center researchers: Selenium will have critical role in prostate cancer treatment
6. Fox Chase Cancer Center researchers identify subset of ovarian cancer patients responsive to Iressa
7. Fox Chase Cancer Center researchers look for silenced genes to monitor kidney cancer patients
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Fox Chase Cancer Center scientists discover key proteins linked to aging and cancer
10. Journalists can register now for ECCO 14 -- the European Cancer Conference
11. Cancer cures could work for canines and humans

Post Your Comments:

(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a ... 2020 annual Inc. 5000 list. The list is the most prestigious ranking of the ... well, and for this year’s list, reported three-year revenue growth of 71 percent. ...
(Date:8/21/2020)... ... August 19, 2020 , ... The ... uniting life science, data science, informatics and IT leaders goes VIRTUAL and announces ... of uncertainty and change, Bio-IT takes the leadership role of keeping our life ...
(Date:8/7/2020)... , ... August 06, 2020 , ... ... industry, is pleased to announce that Eric Chen and Jessica Wong have joined ... Product Management & Strategy, respectively. , Eric Chen heads development efforts for Alucio’s ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech , ... Solutions, in a one hour live webinar on Thursday, August 13, 2020 ... for drugs and medical devices. Specifically, for medical devices, the NMPA has departments dealing ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , ... and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting ... utilize existing data in order to identify and prioritize patients for care. , ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem cell therapy ... stem cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or ... some form of Alzheimers dementia, and the incidence continues to increase as individuals live ...
Breaking Biology Technology:
Cached News: